Maintained immunogenicity of chronic myeloid leukemia-derived dendritic cells in the presence of imatinib mesylate: implication for vaccination regimens.
Westers
T M
TM
Janssen
J J W M
JJ
Houtenbos
I
I
Snoijs
N C L
NC
van de Loosdrecht
A A
AA
Ossenkoppele
G J
GJ
D015703:Antigens, CD / Q000378:metabolism; D001549:Benzamides; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000187:drug effects* / Q000276:immunology*; D004305:Dose-Response Relationship, Drug; D016044:Fusion Proteins, bcr-abl / Q000187:drug effects / Q000276:immunology; D006801:Humans; D000068877:Imatinib Mesylate; D007114:Immunization; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy; D010879:Piperazines / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D014611:Vaccination
D015703:Antigens, CD; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl